BrainStorm’s NurOwn® Phase 3 ALS Clinical Trial Now Fully Enrolled
11 oct. 2019 01h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Oct. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that...
BrainStorm Announces Notice of US Patent Allowance for NurOwn® Cellular Therapeutic Technology Platform
07 oct. 2019 08h04 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that...
BrainStorm Cell Therapeutics to Present NurOwn® Phase 2 Biomarker Data at North East Amyotrophic Lateral Sclerosis (NEALS) 18th Annual Meeting
02 oct. 2019 06h45 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development
27 sept. 2019 04h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financial Officer
09 sept. 2019 01h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that...
BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress
06 sept. 2019 01h50 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
BrainStorm Announces Financial Results for the Second Quarter of 2019 and Provides a Corporate Update
13 août 2019 07h30 HE
|
BrainStorm Cell Therapeutics Inc.
Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: Special High-level FDA Meeting, Continued Progress in NurOwn® ALS Phase 3 Trialand Progressive MS Phase 2 Trial,...
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Comprehensive Corporate Update
05 août 2019 01h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
Third Clinical Site Initiated for BrainStorm Cell Therapeutic’s Phase 2 Progressive MS Study
02 juil. 2019 08h15 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting
31 mai 2019 01h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and SEATTLE, May 31, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...